Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia

Stefan O. Ciurea, Mei Jie Zhang, Andrea A. Bacigalupo, Asad Bashey, Frederick R. Appelbaum, Omar S. Aljitawi, Philippe Armand, Joseph H. Antin, Junfang Chen, Steven M. Devine, Daniel H. Fowler, Leo Luznik, Ryotaro Nakamura, Paul V. O'Donnell, Miguel Angel Perales, Sai Ravi Pingali, David L. Porter, Marcie R. Riches, Olle T H Ringdén, Vanderson RochaRavi Vij, Daniel J. Weisdorf, Richard E. Champlin, Mary M. Horowitz, Ephraim J. Fuchs, Mary Eapen

Research output: Contribution to journalArticlepeer-review

394 Scopus citations

Abstract

We studied adults with acute myeloid leukemia (AML) after haploidentical (n = 192) and 8/8 HLA-matched unrelated donor (n = 1982) transplantation. Haploidentical recipients received calcineurin inhibitor (CNI), mycophenolate, and posttransplant cyclophosphamide for graft-versus-host disease (GVHD) prophylaxis; 104 patients received myeloablative and 88 received reduced intensity conditioning regimens. Matched unrelated donor transplant recipients received CNI with mycophenolate or methotrexate for GVHD prophylaxis; 1245 patients received myeloablative and 737 received reduced intensity conditioning regimens. In the myeloablative setting, day 30 neutrophil recovery was lower after haploidentical compared with matched unrelated donor transplants (90% vs 97%, P = .02). Corresponding rates after reduced intensity conditioning transplants were 93% and 96% (P = .25). In the myeloablative setting, 3-month acute grade 2-4 (16% vs 33%, P < .0001) and 3-year chronic GVHD (30% vs 53%, P < .0001) were lower after haploidentical compared with matched unrelated donor transplants. Similar differences were observed after reduced intensity conditioning transplants, 19% vs 28% (P = .05) and 34% vs 52% (P = .002). Among patients receiving myeloablative regimens, 3-year probabilities of overall survival were 45% (95% CI, 36-54) and 50% (95% CI, 47-53) after haploidentical and matched unrelated donor transplants (P = .38). Corresponding rates after reduced intensity conditioning transplants were 46% (95% CI, 35-56) and 44% (95% CI, 0.40-47) (P = .71). Although statistical power is limited, these data suggests that survival for patients with AML after haploidentical transplantation with posttransplant cyclophosphamide is comparable with matched unrelated donor transplantation.

Original languageEnglish (US)
Pages (from-to)1033-1040
Number of pages8
JournalBlood
Volume126
Issue number8
DOIs
StatePublished - Aug 20 2015

Bibliographical note

Publisher Copyright:
© 2015, American Society of Hematology. All rights reserved.

Fingerprint

Dive into the research topics of 'Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this